Monogram Orthopedics
Future of Joint Reconstruction.
Overview
Raised: $4,599,145
Total Commitments ($USD)
Dealmaker Securities
07/14/2022
03/16/2023
$500
Equity - Preferred
Series B
RegCF
$10.01
$155,000,000
Rolling Commitments ($USD)
03/30/2023
$18,849
2,249
2016
Healthcare & Pharmaceuticals
HealthTech
B2B2C
Low
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$628,246 |
$0 |
|
COGS |
$458,675 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-11,814,968 |
$-9,068,006 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$5,535,710 |
$5,586,748 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$8,715,366 |
$8,115,888 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$0 |
$0 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Monogram Orthopedics | 05/22/2023 | Dealmaker Securities | $246,000,000 | $15,958,364 | Equity - Common | Funded | RegA+ |
| Monogram Orthopedics | 04/27/2023 | Republic | $246,000,000 | $233,363 | Equity - Common | Funded | RegA+ |
| Monogram Orthopedics | 03/15/2023 | Dealmaker Securities | $155,000,000 | $4,599,145 | Equity - Preferred | Funded | RegCF |
| Monogram Orthopaedics | 02/17/2022 | StartEngine | $89,000,000 | $23,648,853 | Equity - Preferred | Funded | RegA+ |
| Monogram Orthopaedics | 01/15/2021 | StartEngine | $89,900,000 | $2,965,501 | Equity - Preferred | Funded | Test the Waters / RegA+ |
| Monogram Orthopaedics | 03/30/2020 | SeedInvest | $21,250,000 | $14,588,668 | Equity - Preferred | Funded | RegA+ |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Analyst Report
Higher precision and faster surgeries. That’s the name of the game with Monogram.
At first glance, this may seem too futuristic (and borderline impossible).
I’m here to tell you that Monogram has nearly done it. The company is conducting live surgical demonstrations of its robot for the orthopedic community and is gearing up for FDA submission.
Once the company’s robot is approved by the FDA, Monogram will launch its first-generation knee offering with generic implants. Once this has been successfully rolled out to hospitals, the company will release its second generation of implants: 3D-printed implants that closely match a patient’s anatomy and stand to disrupt this space in a major way.